Lifileucel Clinical Trials (2026): 10 Studies for Metastatic Melanoma & Unresectable Melanoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Lifileucel clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Metastatic Melanoma & Unresectable Melanoma) and 1,698 total planned enrollment. 2 Phase 3 Lifileucel trials and 5 Phase 2 are listed. 4 Lifileucel clinical trials are actively recruiting at 69 U.S. sites across 28 states. Most recent activity: NCT07288203 (Dec 2033).
Where to Participate: All Lifileucel Trial Sites in the U.S. (69 sites across 28 states)
Every actively recruiting Lifileuceltrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama at Birmingham: The Kirklin Clinic | Birmingham35233 | NCT05727904 | Map |
| AZ | Honor Health | Phoenix85016 | NCT06481592 | Map |
| AZ | Mayo Clinic | Phoenix85054 | NCT06743126 | Map |
| AZ | Honor Health Research Institute | Scottsdale85258 | NCT06743126 | Map |
| CA | City of Hope | Duarte91010 | NCT05727904 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT06743126 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06743126 | Map |
| CA | UCLA Hematology/Oncology | Los Angeles90024 | NCT06743126 | Map |
| CA | University of Southern California | Los Angeles90007 | NCT06481592 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90007 | NCT05727904 | Map |
| CA | California Pacific Medical Center | San Francisco94107 | NCT05727904 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT06743126 | Map |
| CA | Stanford Cancer Center | Stanford94305 | NCT06743126 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT05727904 | Map |
| CO | University of Colorado, Anschutz Medical Campus | Aurora80045 | NCT06743126 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT06743126 | Map |
| FL | University of Miami - Sylvester Comprehensive Cancer Cente | Miami33136 | NCT06743126 | Map |
| FL | Orlando Health | Orlando32806 | NCT06481592 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT05727904 | Map |
| FL | H. Lee Moffitt Cancer Center and Research Institute, Inc. | Tampa33612 | NCT06481592 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06743126 | Map |
| GA | Augusta University | Augusta30912 | NCT06481592 | Map |
| IL | University of Chicago Medical Center | Chicago60637 | NCT06743126 | Map |
| KY | UofL Health - Brown Cancer Center | Louisville40202 | NCT06481592 | Map |
| MD | University of MD Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT06743126 | Map |
| MD | National Cancer Institute | Bethesda20814 | NCT05727904 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06743126 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06743126 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06743126 | Map |
| MI | Barbara Ann Karmanos Cancer Hospital | Detroit48201 | NCT06481592 | Map |
| MI | Henry Ford Health | Detroit48202 | NCT05727904 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT05727904 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06743126 | Map |
| NH | Dartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer Center | Lebanon03756 | NCT05727904 | Map |
| NJ | MD Anderson Cancer Center at Cooper | Camden08103 | NCT05727904 | Map |
| NJ | Atlantic Health System/Morristown Medical Center | Morristown07960 | NCT06743126 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14203 | NCT06481592 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05607095 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT06743126 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06743126 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT05607095 | Map |
| NY | University of Rochester | Rochester14642 | NCT06743126 | Map |
| NC | UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06743126 | Map |
| OH | Oncology Hematology Care | Cincinnati45226 | NCT05727904 | Map |
| OH | Cleveland Clinic, Taussig Cancer Institute | Cleveland44195 | NCT06743126 | Map |
| OH | Ohio State University | Columbus43210 | NCT06743126 | Map |
| OH | Ohio State University | Columbus43201 | NCT05727904 | Map |
| OK | University of Oklahoma | Oklahoma City73117 | NCT06481592 | Map |
| OR | Providence Cancer Institute Franz Clinic | Portland97213 | NCT06743126 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06743126 | Map |
| PA | Thomas Jeffersion University, Sidney Kimmel Cancer Center | Philadelphia19107 | NCT06743126 | Map |
| PA | University of Pennsylvania, Abramson Cancer Center | Philadelphia19104 | NCT06743126 | Map |
| PA | Allegheny Health | Pittsburgh15524 | NCT06481592 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT05727904 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT06743126 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06743126 | Map |
| SD | Avera Medical Group Oncology | Sioux Falls57105 | NCT06481592 | Map |
| TN | Baptist Cancer Center | Bartlett37920 | NCT05727904 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06743126 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT05727904 | Map |
| TX | Baylor University | Dallas75246 | NCT06743126 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06743126 | Map |
| TX | MD Anderson Cancer Center - U of Texas | Houston77030 | NCT06481592 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT06743126 | Map |
| UT | Huntsman Cancer Institute, University of Utah | Salt Lake City84112 | NCT06743126 | Map |
| UT | Intermountain Health | Salt Lake City84112 | NCT05727904 | Map |
| VA | Virginia Commonwealth University | Richmond23219 | NCT06743126 | Map |
| WA | Swedish Cancer Institute | Edmonds98026 | NCT05727904 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06743126 | Map |
Lifileucel clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|---|
| P1 | 1 | 2 | 3 | ||
| P2 | 1 | 1 | 2 | 1 | 5 |
| P3 | 2 | 2 |
Recruiting Lifileucel clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06743126 | SUPRAMESUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | P3 | Melanoma, Cutaneous Malignant | 360 | Jan 2025 |
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | P3 | Metastatic Melanoma | 670 | Mar 2023 |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | P2 | Endometrial Cancer | 60 | Oct 2024 |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | P1 | Uveal Melanoma | 40 | Nov 2022 |
Lifileucel clinical trials by indication
Metastatic Melanoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05727904 | — | P3 | recruiting | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. |
| NCT05640193 | — | P1 | active not recruiting | A Study of LN-144 in People With Metastatic Melanoma to the Brain |
| NCT03645928 | — | P2 | terminated | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors |
| NCT02360579 | LN-144 | P2 | completed | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma |
Melanoma (Skin Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07288203 | — | P2 | active not recruiting | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma |
Melanoma, Cutaneous Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06743126 | SUPRAME | P3 | recruiting | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma |
Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06481592 | — | P2 | recruiting | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. |
Clinical Stage IV Cutaneous Melanoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06151847 | — | P2 | completed | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma |
Uveal Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05607095 | — | P1 | recruiting | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma |
Locally Advanced Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05176470 | — | P1 | active not recruiting | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients |
Lifileucel pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SUPRAME | NCT06743126 | P3 | recruiting | Melanoma, Cutaneous Malignant | 360 | — |
| LN-144 | NCT02360579 | P2 | completed | Metastatic Melanoma | 220 | — |
Terminated and withdrawn Lifileucel trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03645928terminatedStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
All Lifileucel trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07288203 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | P2 | active not recruiting | 100 | Iovance Biotherapeutics, Inc. | Nov 2025 | |
| NCT06743126 | SUPRAME | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | P3 | recruiting | 360 | Immatics US, Inc. | Jan 2025 |
| NCT05727904 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | P3 | recruiting | 670 | Iovance Biotherapeutics, Inc. | Mar 2023 | |
| NCT06481592 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | P2 | recruiting | 60 | Iovance Biotherapeutics, Inc. | Oct 2024 | |
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | P1 | recruiting | 40 | Memorial Sloan Kettering Cancer Center | Nov 2022 | |
| NCT05176470 | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | P1 | active not recruiting | 2 | Richard Wu | Jul 2022 | |
| NCT05640193 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | P1 | active not recruiting | 10 | Memorial Sloan Kettering Cancer Center | Nov 2022 | |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | P2 | terminated | 225 | Iovance Biotherapeutics, Inc. | May 2019 | |
| NCT06151847 | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | P2 | completed | 11 | University of Kansas Medical Center | Dec 2023 | |
| NCT02360579 | LN-144 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | P2 | completed | 220 | Iovance Biotherapeutics, Inc. | Sep 2015 |
Lifileucel clinical trials: frequently asked questions
- How many Lifileucel clinical trials are there?
- 10 Lifileucel clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 2 are marked completed.
- Are Lifileucel clinical trials recruiting in 2026?
- Yes — 4 Lifileucel trials are actively recruiting in 2026, with 69 U.S. sites across 28 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Lifileucel being studied for?
- Lifileucel is being studied for Metastatic Melanoma, Unresectable Melanoma, Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Melanoma, Cutaneous Malignant and 11 more. The trials are grouped by indication on this page.
- What phase is Lifileucel in?
- Lifileucel clinical trials span 2 Phase 3, 5 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Lifileucel clinical trials?
- The lead sponsor across the most Lifileucel trials is Iovance Biotherapeutics, Inc., with 4 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Lifileucelas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: